Global Opioid-Induced Constipation Treatment Market Statistics, Development and Growth 2017 to 2023
Summary – A New Market Study, “Global
Opioid-Induced Constipation Treatment Market: Market Estimation, Dynamics,
Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023” Has Been Featured On
Wiseguyreports.
Opioid-Induced Constipation Treatment
Market Reports
Global
Opioid-Induced Constipation Treatment Market are the drugs used for its pain
relieving properties in non-cancer and chronic pain. The adverse effects
associated with the opioids are decreasing gastrointestinal tract’s motility,
making patient’s strain, and making of solid discharges. Furthermore, long-term
use of opioids cause harm to the sensory system, limits the release of
endogenous opioids such as endorphins. Adults are most likely to prone to
opioid-induced constipation owing to less immobility, poor diet, and fluid
intake. The symptoms associated with the opioid-induced constipation are
included dry and hard tools, leathery feeling, painful defecation, bulged
abdomen, and loss of appetite.
The
opioid-induced constipation treatment market growing at a significant CAGR due
to rise in the aging population using opioid analgesics for chronic pains.
Increase in the illicit use of medications, prolonged usage of opioids in the
treatment of pain, an increase in the prevalence of cancer is anticipated to
boost the global opioid-induced constipation treatment market. Furthermore,
launching of newer drugs, growing FDA approvals, positive outcomes in clinical
trials, and rise in the healthcare expenditure are expected to propel the
opioid-induced constipation treatment market over the forecast period. However,
lack of awareness regarding opioid-induced constipation in patients, the
absence of treatment innovations, a high cost of newer pharmaceuticals, adverse
effects, including nausea, a risk of heart problems and strokes associated with
these drugs and unfavorable reimbursement policies expected to hamper the
growth of the opioid-induced constipation treatment market.
The
opioid-induced constipation treatment market is segmented on the basis of drug
type, formulation type, route of administration, and distribution channel
Based on drug
type, opioid-induced constipation treatment market has been segmented into the
following
Peripherally
restricted μ-opioid receptor antagonists
Non-selective
opioid antagonists
μ -opioid
receptor antagonists
Locally
acting chloride channel activators
Based on
formulation type, opioid-induced constipation treatment market has been
segmented into the following
Solids
Semi-solids
Liquids
Based on
route of administration, opioid-induced constipation treatment market has been
segmented into the following
Oral
Parenteral
(Subcutaneous Injection)
Based on
distribution channel, opioid-induced constipation treatment market has been
segmented into the following
Drugstore
Retail
pharmacies
Hospital
pharmacies
The Global
Opioid-Induced Constipation Treatment Market is in the growing stage, several
players are actively engaged in the development of the opioid-induced
constipation treatment market products. Major acquisitions and collaborations
among companies to commercialize opioid-induced constipation treatment market
products to drive the market growth. For instance, in March 2015, the
co-commercialization agreement for Movenpick signed by AstraZeneca and Daiichi
Sankyo, and in October 2014, the entry of Takeda and Sucampo into a global
licensing, development, and commercialization agreement for Amitiza are
expected to boost the global opioid-induced constipation treatment market.
Launching of new products, approval of new drugs from various regulatory
bodies, and pipeline products under clinical trials are the key factors
fuelling the growth of the opioid-induced constipation treatment market. For
instance, Linaclotide was approved by the FDA in August 2012 and by the
European Medicines Agency for the treatment in adults with
constipation-predominant irritable bowel syndrome and chronic idiopathic
constipation.
Geographically,
Global Opioid-Induced Constipation Treatment Market has been segmented into
following regions Viz. North America, Europe, Asia-Pacific, Latin America, and
Middle East & Africa. North America holds the largest share in the
opioid-induced constipation treatment market followed by Europe and
Asia-Pacific. North America holds the largest share due to expanding the base
of opioid-induced constipation patients, According to the American Society of
Interventional Pain Physician, in 2013, the U.S. alone was responsible for
nearly 80% of the global consumption of opioids. Europe accounts for the
significant share in the opioid-induced constipation treatment market owing to
increased demand for opioid analgesics in various European countries such as
UK, France, Spain, Germany etc. However, growing elderly population in India
and China, and rise in healthcare spending are creating the huge growth opportunity
for the players in Asia-Pacific region. Apart from that, Latin America and the
Middle East are the potential areas for the growth of opioid-induced
constipation treatment market because of the increase in opioid-induced
constipation sufferers.
Some of the
players in the opioid-induced constipation treatment market are GlaxoSmithKline
plc (U.K.), AstraZeneca U.K), Pfizer Inc. (U.S.), SLA Pharma AG (U.K.), AIKO
Biotechnology, Inc. (U.S.), Cubist Pharmaceuticals (Merck & Co.) (U.S.),
Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH
(Germany), Bayer AG (Germany), Valeant Pharmaceuticals International Inc.
(Canada), Abbott Laboratories (U.S.), Purdue Pharma LP (U.S.) Shionogi Inc.
(U.S.) and Cosmo Pharmaceuticals N.V. (Ireland) to name a few.
In March
2017, FDA approved Symphonic (Naldemedine) for the treatment of Opioid-Induced
Constipation, which was manufactured by Purdue Pharma LP and Shionogi
In March
2016, AstraZeneca announced that it has entered into an agreement with ProStrakan
Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., for the rights to Moventig
(Naloxegol) in the European Union (EU)
Report
Outline:
The report
provides granular level information about the market size, regional market
share, and forecast from 2017-2023
The report
covers in-detail insights about the competitor’s overview, key findings, and
their key strategies
The report
outlines drivers, restraints, challenges, and trends that are currently faced
by the industry
The report
tracks recent innovations, key developments and startup’s details that are
working in the industry
The report
provides plethora of information about market entry strategies, regulatory
framework and reimbursement scenario
For More Details : https://www.wiseguyreports.com/reports/2753880-global-opioid-induced-constipation-treatment-market-market-estimation-dynamics-regional
About Us:
Wise Guy Reports Is Part Of The Wise Guy Research Consultants Pvt. Ltd. And Offers Premium Progressive Statistical Surveying, Market Research Reports, Analysis & Forecast Data For Industries And Governments Around The Globe.
Contact Us:
Norah
Trent
Ph: +162-825-80070
(Us)
Ph: +44 2035002763 (Uk)
Comments
Post a Comment